562 related articles for article (PubMed ID: 18641030)
1. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
Mohty M; Boiron JM; Damaj G; Michallet AS; Bay JO; Faucher C; Perreau V; Bilger K; Coso D; Stoppa AM; Tabrizi R; Gastaut JA; Michallet M; Maraninchi D; Blaise D
Bone Marrow Transplant; 2004 Jul; 34(1):77-84. PubMed ID: 15133485
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
4. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A;
Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047
[TBL] [Abstract][Full Text] [Related]
5. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
6. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
[TBL] [Abstract][Full Text] [Related]
8. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
9. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Kröger N; Shaw B; Iacobelli S; Zabelina T; Peggs K; Shimoni A; Nagler A; Binder T; Eiermann T; Madrigal A; Schwerdtfeger R; Kiehl M; Sayer HG; Beyer J; Bornhäuser M; Ayuk F; Zander AR; Marks DI;
Br J Haematol; 2005 Jun; 129(5):631-43. PubMed ID: 15916686
[TBL] [Abstract][Full Text] [Related]
10. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
11. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma.
Kröger N; Einsele H; Derigs G; Wandt H; Krüll A; Zander A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):861-4. PubMed ID: 20139025
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
Tanosaki R; Uike N; Utsunomiya A; Saburi Y; Masuda M; Tomonaga M; Eto T; Hidaka M; Harada M; Choi I; Yamanaka T; Kannagi M; Matsuoka M; Okamura J
Biol Blood Marrow Transplant; 2008 Jun; 14(6):702-8. PubMed ID: 18489996
[TBL] [Abstract][Full Text] [Related]
15. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
Kröger N; Shimoni A; Schilling G; Schwerdtfeger R; Bornhäuser M; Nagler A; Zander AR; Heinzelmann M; Brand R; Gahrton G; Morris C; Niederwieser D; de Witte T
Br J Haematol; 2010 Jan; 148(2):323-31. PubMed ID: 19912215
[TBL] [Abstract][Full Text] [Related]
16. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
Kröger N; Zabelina T; Binder T; Ayuk F; Bacher U; Amtsfeld G; Lellek H; Schrum J; Erttmann R; Eiermann T; Zander A
Biol Blood Marrow Transplant; 2009 Apr; 15(4):454-62. PubMed ID: 19285633
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
20. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution.
Nakai K; Mineishi S; Kami M; Saito T; Hori A; Kojima R; Imataki O; Hamaki T; Yoshihara S; Ohnishi M; Kim SW; Ando T; Fumitoh A; Kanda Y; Makimoto A; Tanosaki R; Kanai S; Heike Y; Ohnishi T; Kawano Y; Wakasugi H; Takaue Y
Transplantation; 2003 Jun; 75(12):2135-43. PubMed ID: 12829926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
